

Existencia 47
Legal

CONFIRMATION

The undersigned, Christian Rehm and Felix Senn, as authorized signatories of NOVARTIS AG, a company organized and existing under the laws of Switzerland with main offices at CH – 4002 Basel. Expressly make the following statements:

We hereby confirm that Novartis Pharma AG and Novartis Lateinamerika AG are directly and indirectly a 100 % subsidiary of Novartis AG, Switzerland, as reflected in the consolidated financial statements of the Novartis Group as of December 31 2015, whose financial information has been officially certified by external auditors, and is public through its website www.novartis.com.

On the other hand, we declare that Novartis AG is headquartered in Basel, Switzerland, and is registered with the Commercial Registry of the Canton of Basel under No. CHE-103.867.266 (former CH-270.3.002.061-2) of March 1, 1996.

Appended are pages 224, 225 and 226 "Principal Group Subsidiaries and Associated Companies" from the Annual Report dated December 31, 2014, duly certified

Date: 12th January 2016

CONFIRMACION

Nosotros, Christian Rehm y Felix Senn, autorizados por NOVARTIS AG, una sociedad organizada y existentes bajo las leyes de Suiza con oficinas principales en CH – 4002 Basilea. En forma expresa lo siguiente:

Confirmamos que Novartis Pharma AG y Novartis Lateinamerika son directamente e indirectamente en un 100% subsidiarias de Novartis AG, Suiza, según se desprende de los Estados Contables Consolidados del Grupo NOVARTIS al 31 de diciembre de 2015, cuya información financiera ha sido oficialmente certificada por los auditores externos, y es de dominio público a través de su página web www.novartis.com.

Por otro lado, declaramos que NOVARTIS AG tiene su sede social en Basilea, Suiza, y se encuentra inscripta en el Registro Público de Comercial del Cantón de Basilea, bajo el No. CHE-103.867.266 (ex CH-270.3.002.061-2) del 1 de marzo de 1996.

Se anexan las páginas 224, 225 and 226 "Principal Group Subsidiaries and Associated Companies" del Reporte Anual al 31 de diciembre de 2014, debidamente certificado.

Fecha: 12 de enero de 2016

Novartis AG

Signed by: /
Firmado por:

Ch. Rehm

F. Senn

Title / Título:

Authorized Signatories both / Personas Autorizadas

32. Principal Group Subsidiaries and Associated Companies

As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities	As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities
Argentina				Colombia			
Novartis Argentina S.A., Buenos Aires	ARS 231.3 m	100	⬆️⬆️	Novartis de Colombia S.A., Santafé de Bogotá	COP 7.9 bn	100	⬆️⬆️
Alcon Laboratorios Argentina S.A., Buenos Aires	ARS 83.9 m	100	⬆️	Laboratorios Alcon de Colombia S.A., Santafé de Bogotá	COP 20.9 m	100	⬆️
Sandoz S.A., Buenos Aires	ARS 88.0 m	100	⬆️				
Australia				Croatia			
Novartis Australia Pty Ltd., North Ryde, NSW	AUD 11.0 m	100	⬆️	Sandoz d.o.o., Zagreb	HRK 25.6 m	100	⬆️
Novartis Pharmaceuticals Australia Pty Ltd., North Ryde, NSW	AUD 3.8 m	100	⬆️⬆️				
Alcon Laboratories (Australia) Pty Ltd., Frenchs Forest, NSW	AUD 2.6 m	100	⬆️	Czech Republic			
Sandoz Pty Ltd., North Ryde, NSW	AUD 11.6 m	100	⬆️	Novartis s.r.o., Prague	CZK 51.5 m	100	⬆️
Novartis Consumer Health Australasia Pty Ltd., Melbourne, Victoria	AUD 7.6 m	100	⬆️⬆️	Sandoz s.r.o., Prague	CZK 44.7 m	100	⬆️
Novartis Animal Health Australasia Pty Ltd., North Ryde, NSW	AUD 3.0 m	100	⬆️⬆️				
Austria				Denmark			
Novartis Austria GmbH, Vienna	EUR 1.0 m	100	⬆️	Novartis Healthcare A/S, Copenhagen	DKK 14.0 m	100	⬆️
Novartis Pharma GmbH, Vienna	EUR 1.1 m	100	⬆️	Alcon Nordic A/S, Copenhagen	DKK 0.5 m	100	⬆️
Alcon Ophthalmika GmbH, Vienna	EUR 36 336.4	100	⬆️	Sandoz A/S, Copenhagen	DKK 8.0 m	100	⬆️
Sandoz GmbH, Kundl	EUR 32.7 m	100	⬆️⬆️⬆️⬆️				
EBEWE Pharma Ges.m.b.H. Nfg., Unterach am Attersee	EUR 1.0 m	100	⬆️⬆️⬆️	Ecuador			
				Novartis Ecuador S.A., Quito	USD 4.0 m	100	⬆️
Bangladesh				Egypt			
Novartis (Bangladesh) Limited, Gazipur	BDT 162.5 m	60	⬆️⬆️	Novartis Pharma S.A.E., Cairo	EGP 33.8 m	99	⬆️⬆️
				Sandoz Egypt Pharma S.A.E., New Cairo	EGP 250 000	100	⬆️
Belgium				Finland			
N.V. Novartis Pharma S.A., Vilvoorde	EUR 7.1 m	100	⬆️	Novartis Finland Oy, Espoo	EUR 459 000	100	⬆️
S.A. Alcon-Couvreur N.V., Puurs	EUR 360.6 m	100	⬆️⬆️				
N.V. Alcon S.A., Vilvoorde	EUR 141 856	100	⬆️	France			
N.V. Sandoz S.A., Vilvoorde	EUR 19.2 m	100	⬆️	Novartis Groupe France S.A., Rueil-Malmaison	EUR 103.0 m	100	⬆️
N.V. Novartis Consumer Health S.A., Vilvoorde	EUR 4.3 m	100	⬆️	Novartis Pharma S.A.S., Rueil-Malmaison	EUR 43.4 m	100	⬆️⬆️⬆️
				Laboratoires Alcon S.A., Rueil-Malmaison	EUR 12.9 m	100	⬆️⬆️
Bermuda				Sandoz S.A.S., Levallois-Perret	EUR 5.4 m	100	⬆️
Triangle International Reinsurance Ltd., Hamilton	CHF 1.0 m	100	⬆️	Novartis Santé Familiale S.A.S., Rueil-Malmaison	EUR 21.9 m	100	⬆️⬆️
Novartis Securities Investment Ltd., Hamilton	CHF 30 000	100	⬆️	Novartis Santé Animale S.A.S., Rueil-Malmaison	EUR 900 000	100	⬆️⬆️
Novartis International Pharmaceutical Ltd., Hamilton	CHF 20 000	100	⬆️⬆️⬆️⬆️				
Trinity River Insurance Co. Ltd., Hamilton	USD 370 000	100	⬆️	Germany			
				Novartis Deutschland GmbH, Wehr	EUR 155.5 m	100	⬆️
Brazil				Novartis Pharma GmbH, Nuremberg	EUR 25.6 m	100	⬆️⬆️
Novartis Biociências S.A., São Paulo	BRL 265.0 m	100	⬆️⬆️	Novartis Pharma Produktions GmbH, Wehr	EUR 2.0 m	100	⬆️
Sandoz do Brasil Indústria Farmacêutica Ltda., Cambé, PR	BRL 190.0 m	100	⬆️⬆️⬆️	Alcon Pharma GmbH, Freiburg	EUR 512 000	100	⬆️
Novartis Saúde Animal Ltda., São Paulo	BRL 50.7 m	100	⬆️⬆️	WaveLight GmbH, Erlangen	EUR 6.6 m	100	⬆️
				CIBA Vision GmbH, Grosswallstadt	EUR 15.4 m	100	⬆️⬆️⬆️
Canada				Sandoz International GmbH, Holzkirchen	EUR 100 000	100	⬆️
Novartis Pharmaceuticals Canada Inc., Dorval/Quebec	CAD 0 ²	100	⬆️⬆️	Sandoz Pharmaceuticals GmbH, Holzkirchen	EUR 5.1 m	100	⬆️
Alcon Canada Inc., Mississauga, Ontario	CAD 0 ²	100	⬆️	Sandoz Industrial Products GmbH, Frankfurt a. M.	EUR 2.6 m	100	⬆️⬆️
CIBA Vision Canada Inc., Mississauga, Ontario	CAD 1	100	⬆️⬆️	1 A Pharma GmbH, Oberhaching	EUR 26 000	100	⬆️
Sandoz Canada Inc., Boucherville, Quebec	CAD 76.8 m	100	⬆️⬆️⬆️	Salutas Pharma GmbH, Barleben	EUR 42.1 m	100	⬆️⬆️
Novartis Consumer Health Canada Inc., Mississauga, Ontario	CAD 159 776	100	⬆️	Hexal AG, Holzkirchen	EUR 93.7 m	100	⬆️⬆️⬆️
Novartis Animal Health Canada Inc., Charlottetown, Prince Edward Island	CAD 180 496	100	⬆️⬆️	Novartis Vaccines and Diagnostics GmbH, Marburg	EUR 5.0 m	100	⬆️⬆️⬆️
				Novartis Vaccines Vertriebs GmbH, Holzkirchen	EUR 26 000	100	⬆️⬆️⬆️
Chile				Novartis Consumer Health GmbH, Munich	EUR 14.6 m	100	⬆️⬆️⬆️
Novartis Chile S.A., Santiago de Chile	CLP 2.0 bn	100	⬆️	Novartis Tiergesundheits GmbH, Munich	EUR 256 000	100	⬆️
Alcon Laboratorios Chile Limitada, Santiago de Chile	CLP 2.0 bn	100	⬆️				
				Gibraltar			
China				Novista Insurance Limited, Gibraltar	CHF 130.0 m	100	⬆️
Beijing Novartis Pharma Co., Ltd., Beijing	USD 30.0 m	100	⬆️⬆️				
Novartis Pharmaceuticals (HK) Limited, Hong Kong	HKD 200	100	⬆️	Greece			
China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai	USD 133.0 m	100	⬆️	Novartis (Hellas) S.A.C.I., Metamorphosis/Athens	EUR 23.4 m	100	⬆️
Suzhou Novartis Pharma Technology Co., Ltd., Changshu	USD 97.4 m	100	⬆️	Alcon Laboratories Hellas Commercial & Industrial S.A., Maroussi/Athens	EUR 5.7 m	100	⬆️
Shanghai Novartis Trading Ltd., Shanghai	USD 2.5 m	100	⬆️				
Alcon Hong Kong Limited, Hong Kong	HKD 77 000	100	⬆️	Hungary			
Alcon (China) Ophthalmic Product Co., Ltd., Beijing	USD 2.2 m	100	⬆️	Novartis Hungary Healthcare Limited Liability Company, Budapest	HUF 545.6 m	100	⬆️
Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan	USD 22.0 m	100	⬆️⬆️	Sandoz Hungary Limited Liability Company, Budapest	HUF 853.0 m	100	⬆️
Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Hangzhou	CNY 46.8 m	85	⬆️⬆️				
Shanghai Novartis Animal Health Co., Ltd., Shanghai	CHF 21.6 m	100	⬆️⬆️	India			
				Novartis India Limited, Mumbai	INR 159.8 m	75	⬆️
				Novartis Healthcare Private Limited, Mumbai	INR 60.0 m	100	⬆️
				Alcon Laboratories (India) Pte Limited, Bangalore	INR 1.1 bn	100	⬆️
				Sandoz Private Limited, Mumbai	INR 32.0 m	100	⬆️⬆️
				Indonesia			
				PT Novartis Indonesia, Jakarta	IDR 7.7 bn	100	⬆️⬆️
				PT CIBA Vision Batam, Batam	IDR 11.9 bn	100	⬆️⬆️
				Ireland			
				Novartis Ireland Limited, Dublin	EUR 25 000	100	⬆️
				Novartis Ringaskiddy Limited, Ringaskiddy, County Cork	EUR 2.0 m	100	⬆️
				Alcon Laboratories Ireland Limited, Cork City	EUR 541 251	100	⬆️



As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities	As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities
Italy				Russian Federation			
Novartis Farma S.p.A., Origgio	EUR 18.2 m	100	⊠ ⊠ ▽ ▲	Novartis Pharma LLC, Moscow	RUB 20.0 m	100	⊠
Alcon Italia S.p.A., Milan	EUR 3.7 m	100	⊠	Alcon Farmaceutika LLC, Moscow	RUB 44.1 m	100	⊠
Sandoz S.p.A., Origgio	EUR 679 900	100	⊠	ZAO Sandoz, Moscow	RUB 57.4 m	100	⊠
Sandoz Industrial Products S.p.A., Rovereto	EUR 2.6 m	100	▽	Novartis Neva LLC, St. Petersburg	RUB 500.0 m	100	▽
Novartis Vaccines and Diagnostics S.r.l., Siena	EUR 41.6 m	100	⊠ ▽ ▲	Novartis Consumer Health LLC, Moscow	RUB 80.0 m	100	⊠
Novartis Consumer Health S.p.A., Origgio	EUR 2.9 m	100	⊠				
Japan				Saudi Arabia			
Novartis Holding Japan K.K., Tokyo	JPY 10.0 m	100	⊠	Saudi Pharmaceutical Distribution Co. Ltd., Riyadh	SAR 26.8 m	75	⊠
Novartis Pharma K.K., Tokyo	JPY 6.0 bn	100	⊠ ▲				
Alcon Japan Ltd., Tokyo	JPY 500.0 m	100	⊠	Singapore			
Sandoz K.K., Tokyo	JPY 100.0 m	100	⊠ ▽ ▲	Novartis (Singapore) Pte Ltd., Singapore	SGD 100 000	100	⊠
Novartis Animal Health K.K., Tokyo	JPY 50.0 m	100	⊠ ▲	Novartis Singapore Pharmaceutical Manufacturing Pte Ltd., Singapore	SGD 45.0 m	100	▽
				Novartis Asia Pacific Pharmaceuticals Pte Ltd., Singapore	SGD 39.0 m	100	⊠
Luxembourg				Novartis Institute for Tropical Diseases Pte Ltd., Singapore	SGD 2 004	100	▲
Novartis Investments S.à r.l., Luxembourg-Ville	USD 2.6 bn	100	⊠	Alcon Singapore Manufacturing Pte Ltd., Singapore	SGD 101 000	100	▽
Novartis Finance S.A., Luxembourg-Ville	USD 100 000	100	⊠	CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore	SGD 1.0 m	100	▽
Malaysia							
Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur	MYR 3.3 m	100	⊠	Slovakia			
Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya	MYR 1.0 m	100	⊠	Novartis Slovakia s.r.o., Bratislava	EUR 2.0 m	100	⊠
CIBA Vision Johor Sdn. Bhd., Gelang Patah	MYR 5.0 m	100	▽				
Mexico				Slovenia			
Novartis Farmacéutica, S.A. de C.V., Mexico City	MXN 205.0 m	100	⊠ ▽	Lek Pharmaceuticals d.d., Ljubljana	EUR 48.4 m	100	⊠ ⊠ ▽ ▲
Alcon Laboratorios, S.A. de C.V., Mexico City	MXN 5.9 m	100	⊠ ▽	Sandoz Pharmaceuticals d.d., Ljubljana	EUR 1.5 m	100	⊠
Sandoz, S.A. de C.V., Mexico City	MXN 468.2 m	100	⊠ ▽				
Netherlands				South Africa			
Novartis Netherlands B.V., Arnhem	EUR 1.4 m	100	⊠	Novartis South Africa (Pty) Ltd., Kempton Park	ZAR 86.3 m	100	⊠
Novartis Pharma B.V., Arnhem	EUR 4.5 m	100	⊠	Alcon Laboratories (South Africa) (Pty) Ltd., Bryanston, Gauteng	ZAR 201 820	100	⊠
Alcon Nederland B.V., Breda	EUR 18 151	100	⊠	Sandoz South Africa (Pty) Ltd., Kempton Park	ZAR 3.0 m	100	⊠ ▽
Sandoz B.V., Almere	EUR 907 570	100	⊠ ▽				
Novartis Consumer Health B.V., Breda	EUR 23 830	100	⊠ ▽	South Korea			
				Novartis Korea Ltd., Seoul	KRW 24.5 bn	99	⊠
New Zealand				Alcon Korea Ltd., Seoul	KRW 33.8 bn	100	⊠
Novartis New Zealand Ltd., Auckland	NZD 820 000	100	⊠				
Norway				Spain			
Novartis Norge AS, Oslo	NOK 1.5 m	100	⊠	Novartis Farmacéutica, S.A., Barcelona	EUR 63.0 m	100	⊠ ⊠ ▽
				Alcon Cusi S.A., El Masnou	EUR 11.6 m	100	⊠ ▽
Pakistan				Sandoz Farmacéutica, S.A., Madrid	EUR 270 450	100	⊠
Novartis Pharma (Pakistan) Limited, Karachi	PKR 3.9 bn	100	⊠ ▽	Sandoz Industrial Products, S.A., Les Franqueses del Vallès/Barcelona	EUR 9.3 m	100	⊠ ▽ ▲
Panama				Novartis Vaccines and Diagnostics, S.L., Barcelona	EUR 675 450	100	⊠
Novartis Pharma (Logistics), Inc., Ciudad de Panama	USD 10 000	100	⊠	Novartis Consumer Health, S.A., Barcelona	EUR 876 919	100	⊠
Peru				Sweden			
Novartis Biosciences Peru S.A., Lima	PEN 6.1 m	100	⊠	Novartis Sverige AB, Täby/Stockholm	SEK 5.0 m	100	⊠
Philippines				Switzerland			
Novartis Healthcare Philippines, Inc., Makati/Manila	PHP 298.8 m	100	⊠	Novartis International AG, Basel	CHF 10.0 m	100	⊠
Sandoz Philippines Corporation, Manila	PHP 30.0 m	100	⊠ ▽	Novartis Holding AG, Basel	CHF 100.2 m	100	⊠
				Novartis Research Foundation, Basel	CHF 29.3 m	100	⊠
Poland				Novartis Foundation for Management Development, Basel	CHF 100 000	100	⊠
Novartis Poland Sp. z o.o., Warszawa	PLN 44.2 m	100	⊠	Novartis Foundation for Employee Participation, Basel	CHF 100 000	100	⊠
Alcon Polska Sp. z o.o., Warszawa	PLN 750 000	100	⊠	Novartis Sanierungsstiftung, Basel	CHF 2.0 m	100	⊠
Sandoz Polska Sp. z o.o., Warszawa	PLN 25.6 m	100	⊠	Novartis Pharma AG, Basel	CHF 350.0 m	100	⊠ ⊠ ▽ ▲
Lek S.A., Strykow	PLN 11.4 m	100	⊠ ▽	Novartis Pharma Services AG, Basel	CHF 20.0 m	100	⊠
Portugal				Novartis Pharma Schweizerhalle AG, Schweizerhalle	CHF 18.9 m	100	▽
Novartis Portugal SGPS Ltd., Porto Salvo	EUR 500 000	100	⊠	Novartis Pharma Stein AG, Stein	CHF 251 000	100	▽ ▲
Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo	EUR 2.4 m	100	⊠	Novartis Pharma Schweiz AG, Rotkreuz	CHF 5.0 m	100	⊠ ▲
Alcon Portugal-Produtos e Equipamentos Oftalmológicos Ltd., Porto Salvo	EUR 4.5 m	100	⊠	Alcon Switzerland SA, Rotkreuz	CHF 100 000	100	⊠
Sandoz Farmacêutica Ltd., Porto Salvo	EUR 5.0 m	100	⊠	Alcon Pharmaceuticals Ltd., Fribourg	CHF 200 000	100	⊠ ⊠
Novartis Consumer Health – Produtos Farmacêuticos e Nutrição Ltd., Porto Salvo	EUR 100 000	100	⊠	ESBATEch, a Novartis Company GmbH, Schlieren	CHF 14.0 m	100	▲
				Sandoz AG, Basel	CHF 5.0 m	100	⊠ ⊠ ▲
Puerto Rico				Sandoz Pharmaceuticals AG, Risch	CHF 100 000	100	⊠
Ex-Lax, Inc., Humacao	USD 10 000	100	▽	Novartis Vaccines and Diagnostics AG, Basel	CHF 800 000	100	⊠ ▲
Alcon (Puerto Rico) Inc., Catano	USD 15.5	100	⊠	Novartis Consumer Health S.A., Prangins	CHF 30.0 m	100	⊠ ⊠ ▽ ▲
				Novartis Consumer Health Schweiz AG, Rotkreuz	CHF 250 000	100	⊠
Romania				Novartis Animal Health AG, Basel	CHF 101 000	100	⊠ ⊠ ▽ ▲
Sandoz S.R.L., Targu-Mures	RON 105.2 m	100	⊠ ▽				

32. Principal Group Subsidiaries and Associated Companies (Continued)

As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities	As at December 31, 2014	Share/paid-in capital ¹	Equity interest %	Activities
Switzerland (continued)				United States of America (continued)			
Novartis Centre de Recherche Santé Animale S.A., St. Aubin	CHF 250 000	100	▲	Alcon Research, Ltd., Fort Worth, TX	USD 12.5	100	▼ ▲
Roche Holding AG, Basel	CHF 160.0 m	33/6 ³	■	Alcon LenSx, Inc., Aliso Viejo, CA	USD 100	100	▼
Taiwan				WaveTec Vision Systems, Inc., Aliso Viejo, CA	USD 1	100	◆ ▼ ▲
Novartis (Taiwan) Co., Ltd., Taipei	TWD 170.0 m	100	◆ ▼	Sandoz Inc., Princeton, NJ	USD 25 000	100	◆ ▼ ▲
Thailand				Fougera Pharmaceuticals, Inc., Melville, NY	USD 1	100	◆ ▲
Novartis (Thailand) Limited, Bangkok	THB 230.0 m	100	◆	Eon Labs, Inc., Princeton, NJ	USD 1	100	◆ ▼
Alcon Laboratories (Thailand) Ltd., Bangkok	THB 228.1 m	100	◆	Falcon Pharmaceuticals, Ltd., Fort Worth, TX	USD 10	100	◆
Turkey				Novartis Vaccines and Diagnostics, Inc., Cambridge, MA	USD 3.0	100	◆ ▼ ▲
Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.Ş., Istanbul	TRY 98.0 m	100	◆ ▼	Novartis Consumer Health, Inc., Parsippany, NJ	USD 0 ²	100	◆ ▼ ▲
Alcon Laboratuvarlari Ticaret A.Ş., Istanbul	TRY 25.2 m	100	◆	Novartis Animal Health US, Inc., Greensboro, NC	USD 100	100	◆ ▼ ▲
Sandoz Ilac Sanayi ve Ticaret A.Ş., Istanbul	TRY 165.2 m	100	◆ ▼	Venezuela			
United Arab Emirates				Novartis de Venezuela, S.A., Caracas	VEF 1.4 m	100	◆
Novartis Middle East FZE, Dubai	AED 7.0 m	100	◆	Alcon Pharmaceutical, C.A., Caracas	VEF 5.5 m	100	◆
United Kingdom				In addition, the Group is represented by subsidiaries and associated companies in the following countries: Algeria, Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Israel, the Former Yugoslav Republic of Macedonia, Morocco, Ukraine and Uruguay.			
Novartis UK Limited, Frimley/Camberley	GBP 25.5 m	100	■				
Novartis Pharmaceuticals UK Limited, Frimley/Camberley	GBP 5.4 m	100	◆ ▼ ▲	¹ Share/paid-in capital may not reflect the taxable share/paid-in capital amount and does not include any paid-in surplus.			
Novartis Grimsby Limited, Frimley/Camberley	GBP 230 m	100	▼	² Shares without par value			
Alcon Eye Care (UK) Limited, Frimley/Camberley	GBP 550 000	100	◆	³ Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis			
Sandoz Limited, Frimley/Camberley	GBP 2.0 m	100	◆	m = million; bn = billion			
Novartis Vaccines and Diagnostics Limited, Frimley/Camberley	GBP 100	100	◆ ▼	The following describe the various types of entities within the Group:			
Novartis Consumer Health UK Limited, Horsham	GBP 25 000	100	◆ ▼				
Novartis Animal Health UK Limited, Frimley/Camberley	GBP 100 000	100	◆ ▲	■ Holding/Finance: This entity is a holding company and/or performs finance functions for the Group.			
United States of America				◆ Sales: This entity performs sales and marketing activities for the Group.			
Novartis Corporation, East Hanover, NJ	USD 72.2 m	100	■	▼ Production: This entity performs manufacturing and/or production activities for the Group.			
Novartis Finance Corporation, New York, NY	USD 1 002	100	■	▲ Research: This entity performs research and development activities for the Group.			
Novartis Capital Corporation, New York, NY	USD 1	100	■				
Novartis Pharmaceuticals Corporation, East Hanover, NJ	USD 5.2 m	100	◆ ▼ ▲				
Novartis Institutes for BioMedical Research, Inc., Cambridge, MA	USD 1	100	▲				
CoStim Pharmaceuticals, Inc., Cambridge, MA	USD 1	100	▲				
Novartis Institute for Functional Genomics, Inc., San Diego, CA	USD 21 000	100	▲				
Genoptix, Inc., Carlsbad, CA	USD 1	100	◆ ▲				
Alcon Laboratories, Inc., Fort Worth, TX	USD 1 000	100	■ ◆ ▼				
Alcon Refractive Horizons, LLC, Fort Worth, TX	USD 10	100	▼				

33. Risk Assessment Disclosures Required by Swiss Law

The Risk Committee of the Board ensures the Group has implemented an appropriate and effective risk management system and process. It reviews with management and internal audit the identification, prioritization and management of the risks, the accountabilities and roles of the functions involved with risk management, the risk portfolio and the related actions implemented by management. The Risk Committee informs the Board of Directors on a periodic basis.

The Group Risk function coordinates and aligns the risk management processes, and reports to the Risk Committee on a regular basis on risk assessment and risk management. Organizational and process measures have been designed to

identify and mitigate risks at an early stage. Organizationally, the responsibility for risk assessment and management is allocated to the divisions, with specialized Corporate Functions such as Group Financial Reporting & Accounting, Group Treasury, Group Quality Operations, Corporate Health, Safety and Environment, and Business Continuity providing support and controlling the effectiveness of the risk management by the divisions.

Financial risk management is described in more detail in Note 29.

ATTESTATION

I, the undersigned Civil Law Notary in Basel, Switzerland, Dr. Matthias Staehelin, certify herewith that the signatures attached heretofore are the genuine signatures of **Mr. Christian Jakob Rehm**, citizen of Ruschein, Switzerland, residing in MuttENZ, Switzerland; and of **Mr. Felix Senn**, citizen of Glarus, Switzerland, residing in Magden, Switzerland; both acting for **Novartis AG**, in Basel, Switzerland, both as authorized signatories and both with joint signature.


The authenticity of the signatures was established by means of comparison.

BASEL, Switzerland, this 13th (thirteenth) day of January 2016 (two thousand and sixteen)

M. Staehelin, Notar

Dr. M. Staehelin
Notar

Leg.Prot.Nr. 97 /2016



APOSTILLE

(Convention de la Haye du 5 octobre 1961)

1. Country Land **Swiss Confederation, Canton of Basel-City**
Schweizerische Eidgenossenschaft, Kanton Basel-Stadt

This public document
Diese öffentliche Urkunde

2. has been signed by ist unterschrieben von **Dr. iur. Matthias Staehelin**

3. acting in the capacity of in seiner Eigenschaft als **Notary Public**

4. bears the stamp/seal of Sie ist versehen mit dem Stempel/Siegel des/der **Staehelin Matthias**

Certified / Bestätigt

5. at / in **Basel** 6. the / am **13.01.2016**

7. by the durch das **Legalisation Office of the Canton of Basel-City**
Beglaubigungsbüro des Kantons Basel-Stadt

No. / Nr. **66669** tax / Taxe **CHF 20.00**

9. stamp/seal Stempel/Siegel

10. Signature Hanna Lauener
Unterschrift

H. Lauener

CERTIFICACIÓN

Yo, el abajo firmante, Notario Público en materia de Derecho Civil de Basilea, Suiza, Dr. Matthias Staehelin, certifico por medio del presente que las firmas que anteceden son las firmas genuinas del Sr. Christian Jakob Rehm, ciudadano de Ruschein, Suiza, residente de MuttENZ, Suiza; y del Sr. Felix Senn, ciudadano de Glarus, Suiza, residente de Magden, Suiza; ambos actúan a nombre de Novartis AG, en Basilea, Suiza, como sus signatarios autorizados y su firma es conjunta.

La autenticidad de las firmas se estableció mediante comparación.

BASILEA, Suiza, el día 13 (trece) de enero de 2016 (dos mil dieciséis)

(Firma)

Dr. M. Staehelin
Notario

Leg.Prot.Nr. 97 /2016

APOSTILLE (Convention de la Haye du 5 octobre 1961)	
1. País :	Confederación Suiza, Cantón Basilea-Ciudad
El presente documento público	
2. ha sido firmado por	Dr. iur. Matthias Staehelin
3. actuando en calidad de	Notario Público
4. se halla sellado/timbrado con	Staehelin Matthias
Certificado	
5. en Basilea	6. El 13.01.2016
7. por	Oficina de Legalización del Cantón Basilea-Ciudad
8. con el número 66669	Impuesto CHF 20.00
9. Sello/timbre	10. Firma Hanna Lauener
	(Firma)

CANTÓN DE
BASILEA-CIUDAD
LEGALIZACIONES

Certificación de Traductor: Yo, Diego Cornejo Rodríguez, de nacionalidad ecuatoriana, portador de cédula de identidad N° 170592530-1 y miembro certificado de la Asociación de Traductores e Intérpretes del Ecuador ATIEC, certifico que este documento es una fiel traducción del documento original en inglés.